Jason Broderick

Associate Director, Digital Editorial @OncLive

[Jason Broderick @Jasoncology]

Isatuximab Approved in Europe for Relapsed/Refractory Myeloma https://t.co/FEZp5VC3RB #mmsm

[Jason Broderick @Jasoncology]

Olaparib Approaches EU Approval for Frontline Maintenance in Pancreatic Cancer https://t.co/iOOcykuRMX

[Jason Broderick @Jasoncology]

Palbociclib Falls Short in Phase 3 Early Breast Cancer Trial https://t.co/VBYdpg1HhQ #bcsm

[Jason Broderick @Jasoncology]

EU Panel Backs Entrectinib for NTRK + Tumors and ROS1 + NSCLC https://t.co/mSa4dCWOwv #lcsm

[Jason Broderick @Jasoncology]

Alpelisib Nears EU Approval for PIK3CA+ Breast Cancer https://t.co/yB6hCLH437 #bcsm

[Jason Broderick @Jasoncology]

FDA Approves Ramucirumab Plus Erlotinib for Frontline EGFR + NSCLC https://t.co/CufWWE05T7 #ASCO20 #lcsm

[Jason Broderick @Jasoncology]

FDA Approves Atezolizumab Plus Bevacizumab for Frontline Liver Cancer https://t.co/A0Xju5nTmb #ASCO20

[Jason Broderick @Jasoncology]

FDA Approves Atezolizumab Plus Bevacizumab for Frontline HCC https://t.co/A0Xju5nTmb via @onclive

[Jason Broderick @Jasoncology]

Alpelisib Impresses in PI3KCA + Breast Cancer After Progression on CDK Inhibition https://t.co/o3lSbJ7hRx #bcsm #ASCO20

[Jason Broderick @Jasoncology]

NCCN Adds Rucaparib to Prostate Cancer Guidelines https://t.co/zbtsJomwo7 #pcsm

[Jason Broderick @Jasoncology]

FDA Grants Onvansertib Fast Track Designation in KRAS + mCRC https://t.co/7DCcUQjZau

[Jason Broderick @Jasoncology]

FDA Waives ODAC Review of Margetuximab in HER2+ Breast Cancer https://t.co/haJBMvcofQ #bcsm

[Jason Broderick @Jasoncology]

IASLC Survey Illustrates Current Barriers to Molecular Testing in Lung Cancer https://t.co/Eic7zLPvPo #lcsm

[Jason Broderick @Jasoncology]

Belumosudil Impresses in cGVHD, FDA Submission Started https://t.co/zS1891s15y

[Jason Broderick @Jasoncology]

Rucaparib Prostate Cancer Approval Sets Stage for Further Research https://t.co/cNXI3CNX0K #pcsm

[Jason Broderick @Jasoncology]

Immunotherapy Revolutionizes Melanoma Treatment Paradigm https://t.co/vZK2vvmm0v #melsm @YaleCancer @SmilowCancer

[Jason Broderick @Jasoncology]

Selinexor sNDA Submitted to FDA for Earlier Use in Multiple Myeloma https://t.co/iw1SY5SpTw #mmsm

[Jason Broderick @Jasoncology]

FDA Approves Multiple Companion Diagnostics for Olaparib in HRR+ mCRPC https://t.co/9UTEgPOSav #pcsm

[Jason Broderick @Jasoncology]

Dr. Agarwal on the FDA Approval of Olaparib in HRR -Mutant mCRPC https://t.co/eyErFvvbFy #pcsm

[Jason Broderick @Jasoncology]

FDA Approves Olaparib for HRR-Mutant mCRPC https://t.co/GOJq3JcDLz #pcsm